(Hypertension. 2002;39:603.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
From the Departments of Anatomy and Cell Biology (P.S., T.E.L., M.D.C., R.L.D.), Internal Medicine (P.D.S, B.L.D.), and Neurology (B.L.D.), The University of Iowa College of Medicine, Iowa City, Iowa.
Correspondence to Dr Robin L. Davisson, Assistant Professor, Department of Anatomy and Cell Biology, University of Iowa College of Medicine, 1-251 BSB, Iowa City, IA 52242. E-mail robin-davisson{at}uiowa.edu
| Abstract |
|---|
|
|
|---|
Key Words: renin-angiotensin system brain gene regulation
| Introduction |
|---|
|
|
|---|
The RAS in the forebrain neural circuitry containing the subfornical organ (SFO)-supraoptic nucleus (SON) axis is one example of a system that is known to be critically involved in blood pressure and body fluid regulation, yet that remains poorly understood because of difficulties in dissecting it. The SFO, a circumventricular organ, is thought to couple blood-borne signals such as Ang-II with brain structures that trigger endocrine and autonomic reflexes designed to restore homeostasis.2 The hypothalamic nucleus SON, containing magnocellular vasopressinergic neurosecretory cells, receives direct projections from neurons of the SFO.3,4 Stimulation of the SFO-SON pathway is considered to be important in the control of osmolality and blood pressure by affecting the release of vasopressin,5,6 although the precise mechanisms are not known. The RAS has been implicated as an important mediator within this axis,2 and various RAS components are expressed cell-selectively within SFO and SON. For example, angiotensinogen is expressed in neurons and glial cells of the SFO and SON,7,8 whereas Ang-II receptors are expressed specifically within neurons in these regions.911 However, the precise role of the RAS, as well as other signaling systems within this important CV control circuitry, remain to be elucidated.
Cell- and site-selective targeting of the SFO-SON axis with genes that modify the RAS and/or other signaling pathways could help unravel important mechanisms of CV regulation both in health and disease. Replication-deficient recombinant viral vectors have become important tools for gene delivery to the central nervous system (CNS) and other tissues in recent years.1214 Adenovirus (Ad) and lentivirus, such as the feline immunodeficiency virus (FIV), appear to be the most promising vehicles for localized gene transfer to the brain, although each exhibit unique properties. Ad vectors allow highly efficient (although transient) delivery of relatively large transgenes, and infect both neuronal and glial cell types.13 Ad is also known to be taken up by terminals and retrogradely transported to neuronal somata distant to the site of injection.15,16 In contrast, when the envelop protein of the feline immunodeficiency virus is replaced by the envelop protein from the vesicular stomatitis virus (VSV-G), this VSV-G pseudotyped FIV mediates gene transfer predominantly to neurons rather than to nonneuronal cells,17 and retrograde transport is limited to local, but not distant, neuronal somata.17 Additionally, since FIV integrates the transgene into the host genome, transgene expression is highly stable.18 The majority of studies comparing Ad, FIV, and other viral vectors for CNS gene transfer have been carried out in vitro14,19,20 or in cerebellum, cerebrum, or striatum in vivo.13,1618,21,22 In vivo Ad- or FIV-mediated gene transfer to specific CV control regions has not been extensively explored.
We hypothesized that by taking advantage of the unique properties of each of these viral vectors to target gene transfer to appropriate populations of cells within the SFO-SON axis, we could address our long-range goal of dissecting the role of the brain RAS within this important CV control circuitry. The aims of the current study were (1) to establish the feasibility of selectively targeting murine SFO and SON for gene transfer in vivo and (2) to compare Ad and FIV transduction of SFO and SON with respect to cell-type specificity, stability, and local versus distant infectivity through retrograde transport.
| Methods |
|---|
|
|
|---|
Preparation of Viral Vectors
Ad and FIV vectors encoding E. coli ß-galactosidase (Adß-gal and FIVß-gal) driven off the cytomegalovirus promoter were prepared in the Gene Transfer Vector Core Laboratory at The University of Iowa as described in detail previously.13,23 Briefly, the recombinant Ad vector is based on the human adenovirus serotype 5, from which the E1a and E1b replication genes have been deleted.24 The FIV vector construct containing mutant vif and orf2 sequences was cotransfected with a vesicular stomatitis glycoprotein G envelope protein-expressing plasmid.23 FIVß-gal and Adß-gal titers were
3x108 TU/mL and 1x109 pfu/mL, respectively.
Viral Injections Into SFO and SON
Mice were anesthetized with ketamine (90 mg/kg, IP) and acepromazine (1.8 mg/kg, IP), placed in a stereotaxic instrument (David Kopf Instruments) and the skull exposed by an incision. After leveling the skull between lambda and bregma, a burr hole was drilled and a Hamilton syringe was inserted at coordinates (relative to bregma):25 SFO (n=19): midline, 0.2 mm caudal, 2.9 mm ventral; SON (n=18): 3.1 mm either side of midline at 20° angles, 0.6 mm caudal, 5.0 mm ventral. These coordinates placed the injector just dorsal to each site, allowing selective injection without damage to the structure. Titer-matched vector stocks of FIVß-gal (SFO, n=8; SON, n=10) or Adß-gal (SFO, n=11; SON, n=8) were injected in volumes of 200 nL for SFO and 300 nL for SON (bilaterally). Incisions were sutured and mice were kept warm until fully recovered from anesthesia, at which time they were returned to their home cages.
ß-Gal Histochemistry and Double Immunofluorescence
At 1, 3, or 8 weeks after virus injections, mice were sacrificed and perfused transcardially with 0.9% saline followed by 4% paraformaldehyde in PBS. Brains were removed, post-fixed, saturated in 20% sucrose, and cryo-sectioned (coronal, 30 to 40 µm). Some sections were processed for ß-galactosidase activity using 5-bromo-4-chloro-3-indoyl-ß-D-galactopyranoside (X-gal, Boehringer Mannheim), counterstained with eosin, and analyzed by light microscopy as described.13,26 Separate brains were processed for double immunofluorescence for cell-specific detection of ß-galactosidase (ß-gal) protein. Sections were incubated with a rabbit anti-ß-gal antibody (1:500, 5 Prime-3 Prime) combined with either mouse monoclonal anti-MAP-2 (1:500, Sternberger Monoclonal Antibodies) or mouse monoclonal anti-GFAP (1:1000, Chemicon) overnight at 4°C, followed by incubation in Alexa Fluor 488 conjugated goat anti-rabbit IgG (1:200, 2hrs, Molecular Probes) and rhodamine conjugated goat anti-mouse antibody (1:200, 2hrs, Sigma). Mounted sections were analyzed by confocal laser microscopy (Zeiss LSM 510).
Immunohistochemical Analysis of Inflammatory Responses to Viral Injections
A subset of FIVß-gal-injected (n=6) and Adß-gal-injected (n=4) mice were sacrificed at 1, 3, or 8 weeks postinjection, and brains were prepared as described above. Alternating serial sections were X-gal stained (see above) or incubated for 24 hours at 4°C with either rat anti-CD-3 (lymphocytes, 1:200, Novacastra) or anti-F4/80 (macrophages, 1:200, Serotec), followed by biotinylated goat anti-rat IgG, then streptavidin-horseradish peroxidase. Sections were stained with DAB and counterstained with hematoxylin.
Cell Counts
Numbers of ß-gal-positive neuronal and glial cell fragments were scored in three to four corresponding serial sections each for SFO and SON (20 to 40x objective). Cell-type scoring was done both in X-gal-stained sections based on morphological analyses of distinct characteristics of neuronal and glial cell types, and in immunolabeled samples based on dual staining for ß-gal and cell-specific markers.
Data Analysis
Cell counts were calculated as an average number of ß-gal-positive fragments over three to four serial sections per animal, and data were expressed as mean±SEM for each site and time point. Data were analyzed by ANOVA followed by the Students modified t test with Bonferroni correction for multiple comparisons between means using the modified error mean square term from the ANOVA.
| Results |
|---|
|
|
|---|
|
|
Within these sites, there was differential transduction of neuronal and glial cell types with the two viral vectors. In Adß-gal-injected SFO or SON, transgene-positive cells showed neuronal, glial, and microglial morphologies, and when costained for immunofluorescence, expressed both neuronal (MAP-2) and glial (GFAP) marker proteins (Figure 2, top). In contrast, only cells with neuronal morphology were transduced by FIV-ß-gal, with colocalization of ß-gal being limited to MAP-2-immunoreactive cells (Figure 2, bottom). Numbers and types of cells in SFO and SON transduced by the two vectors are summarized in Figure 3. Both neuronal and glial cell types exhibited ß-gal-positive staining in Adß-gal-injected SFO and SON, with a larger proportion of glial cells transduced in the SFO, but approximately equal numbers of transgene-expressing neurons and glia in the SON (Figure 3A). In contrast, injection of FIVß-gal resulted in the exclusive transduction of neurons in both SFO and SON (Figure 3B), with a greater total number of neurons showing ß-gal expression, especially in SFO, compared with Adß-gal-injected sites.
|
There were also differences between the two viruses with regard to stability of transgene expression over time. The pattern and density of ß-gal-positive cells were not significantly changed for as long as 2 months after FIVß-gal injection in either SFO or SON (Figure 3). In contrast, by 8 weeks following Adß-gal administration to SFO or SON, transgene expression in both cell types was reduced by approximately 75% compared with that at 1 and 3 weeks postinjection. Numbers of ß-gal-positive cells were comparable at the 1- and 3-week time points for Adß-gal-infected SFO and SON. Invading lymphocytes and macrophages were detected in and immediately around the injector tract for both FIVß-gal- and saline-treated groups, which most likely represents the reaction to mechanical trauma from the injector itself. No further infiltrate was observed in FIVß-gal-injected SFO and SON at 1, 3, or 8 weeks, whereas CD-3- and F4/80-positive cells were detectable in these sites at the various time points following Ad-ß-gal (data not shown). However, this was a relatively mild response that was not associated with obvious tissue trauma or changes in cell morphology in the injected sites.
Previous studies in other brain regions have shown that Ad can undergo retrograde transport to neuronal soma distant to the site of injection, whereas FIV transport is more limited.16,17 We examined both X-gal- and immunoflourescence-processed sections for ß-gal-positive cells in sites other than those directly injected with FIVß-gal or Adß-gal. Figure 4 shows a representative example of a double-labeled SFO from an animal that had been injected with Adß-gal into SON (bilaterally) 3 weeks earlier. ß-gal was detected in the distant SFO, and was localized to cells with neuronal morphology. The complete lack of colocalization of ß-gal with the glial marker protein GFAP suggests neuronal expression of the transgene in this site (Figure 4). Because SON receives direct short-loop projections from the SFO,4 these results suggest that Adß-gal was able to undergo retrograde transport from terminals in the SON back to neuron somata in the SFO. No other sites contained retrograde labeled cells. Finally, only local transgene expression at the primary site of injection was observed with local FIVß-gal. We found no evidence of ß-gal-positive staining in secondary regions because of either transport or diffusion.
|
| Discussion |
|---|
|
|
|---|
To our knowledge, this is the first report of in vivo delivery of a transgene selectively to the SFO, either directly or indirectly, in any species. An earlier report demonstrated Ad-mediated transduction of cultured rat SFO cells in vitro, but transgene expression was not detected in sections following in vivo administration of the virus.30 The SFO is a complex CNS structure that is thought to provide an interface between blood pressure and volume regulatory signals circulating in the blood, and brain circuitry involved in homeostatic neurohumoral reflexes.2 It has been implicated in normal CV regulation and in the pathogenesis of hypertension for many years,2 although the underlying mechanisms are not known. There are several properties of the SFO that the unique features of the Ad and FIV vectors could potentially be brought to bear on in dissecting this pivotal structure. For example, the RAS, implicated as an important mediator in SFOs coupling of circulating signals with efferent pathways, is expressed cell-selectively in the SFO. Angiotensinogen, the only known substrate of Ang-II production, is expressed primarily in glial cells throughout the brain31 but is highly localized to neurons in a few select nuclei including the SFO.8,7 Ang-II receptors are expressed neuron-selectively within SFO, but other RAS components exist both in glial and neuronal cell types in this site.9 Indeed, a similar cell-specific expression of the various RAS components exists in the SON,32,33 although the significance is unknown. Our data showing neuron-exclusive transduction of SFO and SON with FIV, but equal targeting of glia and neurons in these sites with Ad, lead us to speculate that each of these vectors, harboring genes that modify or disrupt expression of particular RAS genes, could be useful in understanding the significance of the different RAS-containing cell types. Certainly, other signaling molecules in this axis could be similarly targeted.
Another poorly understood attribute of the SFO that could lend itself to investigation by Ad-mediated gene delivery is the relative significance of different subgroups of neurons within this structure that have specific efferent connections.27 It is known that subpopulations of neurons in the outer zone or annulus of the SFO send projections to vasopressin-containing neurons of the hypothalamic paraventricular nucleus (PVN) and SON, to parvocellular neurons of the PVN, and to neurons of the median preoptic nucleus, all sites known to be involved in CV homeostasis.27 Much less is known about the SFO neurons projecting from the core and caudal parts. Our lack of understanding of these various neuronal subgroups is due in part to the lack of investigative methods for selectively manipulating them. Findings in the current study and those of others14 suggest that, by capitalizing on the ability of Ad to be taken up by nerve terminals at the primary injection site and undergo retrograde transport to the cell soma, genes can be delivered to specific subpopulations of neurons that are difficult to approach directly. Our findings suggest that a subgroup of SFO neurons was targeted in vivo by retrograde transport of Adß-gal from the SON, the first such report to our knowledge. A similar strategy has been used to successfully target genes back to neurons of the PVN and SON via pituitary injections of an Ad vector.34 We are currently investigating the feasibility of inducing transgene expression in additional functionally unique subgroups of SFO neurons by selectively injecting Adß-gal into its other sites of projection, eg, PVN and median preoptic nucleus. Additionally, since it has been shown that higher Ad titers at the primary injection site transduce a greater number of cells at a distance in the target region,16,19 we are currently exploring different Ad titers in our studies. Defining a concentration that allows for efficient transport to distant neurons without undue inflammatory responses at the primary injection site is the goal.
In the SFO-SON axis, FIV appears to be the vector of choice for spatially restricting transduction to the site of injection without transgene delivery to a secondary region by retrograde transport or diffusion. We consistently showed highly localized transgene expression in FIVß-gal-injected SFO or SON, with no observed transport or spread of the virus, even with higher titers (data not shown). This may be a consequence of unique characteristics of these sites since Alisky et al reported retrograde transport of FIV to cerebellar nuclei outside of the primary injection site, albeit to nearby sites.17 Another feature of the FIV vector that may be a function of the particular brain region being transduced is the tropism of the virus for neurons. In both the SFO and SON, ß-gal-positive staining was found exclusively in neurons, with no evidence of transgene expression in nonneuronal cells. Studies using FIV in other brain regions report up to 20% of transduced cells being nonneuronal.22 Additionally, FIV has been shown to efficiently transduce some populations of neurons but not others in the cerebellum.17 The mechanism underlying the tropism of the VSV-G pseudotyped FIV is incompletely understood, but differences in expression of the receptor for the virus may play a role in the regional differences in FIV-mediated transduction.29
Consistent with other reports,13 our results indicate that there is a decline in numbers of ß-gal-positive cells with Adß-gal but not FIVß-gal over time. The stability of FIV-mediated gene transfer may in part be due to the well-known feature of lentiviruses to integrate the message into the host genome, whereas adenoviral DNA remains primarily episomal.35,18 Additional hypotheses for transient Ad-mediated gene transfer include a host immune response to infected cells, toxicity of the transgene product, or alterations in the level of transcription associated with the cytomegalovirus promoter over time.13,35
The power of recombinant viral vectors is already being deployed to study central regulation of CV function. Several studies reporting intracerebroventricular administration of viral vectors encoding antisense genes in rats have provided further evidence of the importance of the RAS in blood pressure regulation.36,37 The long-term goal of our work is to capitalize on the unique properties of particular viral vectors to allow selective targeting of transgenes to specific populations of cells within key forebrain sites, including but not limited to the SFO-SON axis. For example, we are currently establishing the tools for generating brain site-selective RAS gene deletion using the Cre-loxP system.38 In particular, we plan to utilize the regional and cell-type specificity of Ad and FIV vectors demonstrated herein to mediate selective delivery of Cre recombinase in mice with floxed genes.38 We believe viral-mediated delivery of Cre and other transgenes will provide a powerful means for dissecting the molecular mechanisms by which key brain regions regulate CV function in health and disease.
| Acknowledgments |
|---|
Received September 24, 2001; first decision November 2, 2001; accepted November 21, 2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. L. Grobe, D. Xu, and C. D. Sigmund An Intracellular Renin-Angiotensin System in Neurons: Fact, Hypothesis, or Fantasy Physiology, August 1, 2008; 23(4): 187 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Lin, Y. Chen, W. Zhang, A. F. Chen, S. Lin, and M. Morris RNA interference shows interactions between mouse brainstem angiotensin AT1 receptors and angiotensin-converting enzyme 2 Exp Physiol, May 1, 2008; 93(5): 676 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Peterson, D. W. Infanger, V. A. Braga, Y. Zhang, R. V. Sharma, J. F. Engelhardt, and R. L. Davisson Longitudinal noninvasive monitoring of transcription factor activation in cardiovascular regulatory nuclei using bioluminescence imaging Physiol Genomics, April 21, 2008; 33(2): 292 - 299. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Feng, X. Yue, H. Xia, S. M. Bindom, P. J. Hickman, C. M. Filipeanu, G. Wu, and E. Lazartigues Angiotensin-Converting Enzyme 2 Overexpression in the Subfornical Organ Prevents the Angiotensin II-Mediated Pressor and Drinking Responses and Is Associated With Angiotensin II Type 1 Receptor Downregulation Circ. Res., March 28, 2008; 102(6): 729 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sinnayah, E. Lazartigues, K. Sakai, R. V. Sharma, C. D. Sigmund, and R. L. Davisson Genetic Ablation of Angiotensinogen in the Subfornical Organ of the Brain Prevents the Central Angiotensinergic Pressor Response Circ. Res., November 10, 2006; 99(10): 1125 - 1131. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Watanabe, T. Y. Hiyama, H. Shimizu, R. Kodama, N. Hayashi, S. Miyata, Y. Yanagawa, K. Obata, and M. Noda Sodium-level-sensitive sodium channel Nax is expressed in glial laminate processes in the sensory circumventricular organs Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R568 - R576. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Noda The Subfornical Organ, a Specialized Sodium Channel, and the Sensing of Sodium Levels in the Brain Neuroscientist, February 1, 2006; 12(1): 80 - 91. [Abstract] [PDF] |
||||
![]() |
Y. Chen, H. Chen, A. Hoffmann, D. R. Cool, D. I. Diz, M. C. Chappell, A. Chen, and M. Morris Adenovirus-Mediated Small-Interference RNA for In Vivo Silencing of Angiotensin AT1a Receptors in Mouse Brain Hypertension, February 1, 2006; 47(2): 230 - 237. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sakai, Y. Hirooka, H. Shigematsu, T. Kishi, K. Ito, H. Shimokawa, A. Takeshita, and K. Sunagawa Overexpression of eNOS in brain stem reduces enhanced sympathetic drive in mice with myocardial infarction Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2159 - H2166. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Duale, S. Kasparov, J. F. R. Paton, and A. G. Teschemacher Differences in transductional tropism of adenoviral and lentiviral vectors in the rat brainstem Exp Physiol, January 1, 2005; 90(1): 71 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Teschemacher, S. Wang, T. Lonergan, H. Duale, H. Waki, J. F. R. Paton, and S. Kasparov Targeting specific neuronal populations using adeno- and lentiviral vectors: applications for imaging and studies of cell function Exp Physiol, January 1, 2005; 90(1): 61 - 69. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Zimmerman, E. Lazartigues, R. V. Sharma, and R. L. Davisson Hypertension Caused by Angiotensin II Infusion Involves Increased Superoxide Production in the Central Nervous System Circ. Res., July 23, 2004; 95(2): 210 - 216. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Phillips A Cre-loxP solution for defining the brain renin-angiotensin system. Focus on "Targeted viral delivery of Cre recombinase induces conditional gene deletion in cardiovascular circuits of the mouse brain" Physiol Genomics, June 17, 2004; 18(1): 1 - 3. [Full Text] [PDF] |
||||
![]() |
P. Sinnayah, T. E. Lindley, P. D. Staber, B. L. Davidson, M. D. Cassell, and R. L. Davisson Targeted viral delivery of Cre recombinase induces conditional gene deletion in cardiovascular circuits of the mouse brain Physiol Genomics, June 17, 2004; 18(1): 25 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Lindley, M. F. Doobay, R. V. Sharma, and R. L. Davisson Superoxide Is Involved in the Central Nervous System Activation and Sympathoexcitation of Myocardial Infarction-Induced Heart Failure Circ. Res., February 20, 2004; 94(3): 402 - 409. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Davisson Physiological genomic analysis of the brain renin-angiotensin system Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R498 - R511. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Zimmerman, E. Lazartigues, J. A. Lang, P. Sinnayah, I. M. Ahmad, D. R. Spitz, and R. L. Davisson Superoxide Mediates the Actions of Angiotensin II in the Central Nervous System Circ. Res., November 29, 2002; 91(11): 1038 - 1045. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||